How Will the Market React to Arrowhead Pharmaceuticals Inc (ARWR) Stock Getting a Bearish Rating

Arrowhead Pharmaceuticals Inc (ARWR) stock is down 17.16% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Arrowhead Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ARWR!

See Full ARWR Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ARWR Stock Today?

Arrowhead Pharmaceuticals Inc (ARWR) stock is higher by 1.06% while the S&P 500 is lower by -0.43% as of 10:32 AM on Friday, Mar 15. ARWR is higher by $0.29 from the previous closing price of $27.42 on volume of 331,929 shares. Over the past year the S&P 500 has gained 31.77% while ARWR is higher by 9.44%. ARWR lost -$2.77 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Arrowhead Pharmaceuticals Inc click here.

More About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. Click Here to get the full Stock Report for Arrowhead Pharmaceuticals Inc stock.